Not applicableStudy completedNCT06080204What this trial is testingReal-world Study on Adjuvant Octreotide Therapy in pNETsWho this might be right forPancreatic Neuroendocrine Tumor G2 Changhai Hospital 411
Testing effectiveness (Phase 2)Looking for participantsNCT05773274What this trial is testingComparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialWho this might be right forMetastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more National Cancer Institute (NCI)
Not applicableActive Not RecruitingNCT04804371What this trial is testingDual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors University Health Network, Toronto 40
Testing effectiveness (Phase 2)UnknownNCT05894486What this trial is testingPhase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors Peking University 40
Not applicableStudy completedNCT03667092What this trial is testingExploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine TumorWho this might be right forMidgut Neuroendocrine Tumors University Hospital, Toulouse 47
Large-scale testing (Phase 3)Active Not RecruitingNCT03375320What this trial is testingTesting Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsWho this might be right forFunctioning Pancreatic Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine Neoplasm+25 more National Cancer Institute (NCI) 298
Testing effectiveness (Phase 2)Study completedNCT02893930What this trial is testingSapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryWho this might be right forPancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Refractory Pancreatic Neuroendocrine Carcinoma National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Study completedNCT01229943What this trial is testingEverolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by SurgeryWho this might be right forAdvanced Pancreatic Neuroendocrine TumorLocally Advanced Pancreatic Neuroendocrine TumorPancreatic Gastrinoma+3 more National Cancer Institute (NCI) 150
Large-scale testing (Phase 3)Study completedNCT01744249What this trial is testingSandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine CarcinomasWho this might be right forNeuroendocrine TumorsAdvanced Cancer Grupo Espanol de Tumores Neuroendocrinos 256
Post-approval studies (Phase 4)Looking for participantsNCT06016855What this trial is testingSurgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forDigestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more Vanderbilt-Ingram Cancer Center 6
Not applicableStudy completedNCT04727723What this trial is testingItalian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETsWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Looking for participantsNCT04665739What this trial is testingTesting Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsWho this might be right forAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine Neoplasm+9 more National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT01841736What this trial is testingPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsWho this might be right forForegut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1+5 more National Cancer Institute (NCI) 171
Large-scale testing (Phase 3)Active Not RecruitingNCT00569127What this trial is testingOctreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorWho this might be right forColorectal Neuroendocrine Tumor G1Gastric Neuroendocrine Tumor G1Neuroendocrine Neoplasm+2 more National Cancer Institute (NCI) 427
Early research (Phase 1)Looking for participantsNCT07150546What this trial is testingCombination External Radiation and PRRT for Large GI Neuroendocrine Tumors.Who this might be right forDigestive System Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1+1 more Emory University 15
Testing effectiveness (Phase 2)Study completedNCT02231762What this trial is testingCombination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Ipsen 57